Ibio Inc (IBIO) has disclosed a new risk, in the Trade Secrets category.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ibio Inc faces significant business risks due to its reliance on intellectual property licensed from third parties, particularly concerning its advanced product candidates, IBIO-600 and IBIO-610. These dependencies are tied to exclusive agreements with AstralBio, which grant Ibio Inc the rights to develop and commercialize these candidates. The termination of these licenses could lead to the loss of critical rights, adversely affecting the company’s ability to bring these products to market. Additionally, disputes over intellectual property or failure by licensors to enforce patents could further jeopardize Ibio Inc’s operations and financial health.
Overall, Wall Street has a Moderate Buy consensus rating on IBIO stock based on 2 Buys.
To learn more about Ibio Inc’s risk factors, click here.